Despite the importance of Dengue virus (DENV) infection in human health, there is not a fully effective vaccine or antiviral treatment against the infection. Since lipids such as cholesterol are required during DENV infection, its uptake and synthesis are increased in infected cells. Ezetimibe is an FDA-approved drug that reduces cholesterol uptake by inhibiting the endocytosis through Niemman-Pick C1-Like 1 (NPC1L1) receptor, expressed on the membrane of enterocytes and hepatocytes. Our results indicate that an increase in the amount of NPC1L1 occurs on the surface of Huh-7 cells during DENV infection, which correlates with an increase in cholesterol levels. Blockage of NPC1L1 with ezetimibe in concentrations up to 50 μM does not reduce cell viability but diminished total cellular cholesterol, the percentage of infected cells, viral yield, viral RNA and protein synthesis without affecting DENV binding and/or entry to Huh-7 cells. Moreover, ezetimibe inhibited DENV replicative complex formation and lipid droplets accumulation. All these results indicate that ezetimibe is an excellent drug to inhibit DENV infection and confirm that cholesterol is a key target to inhibit viral infection.
Introduction
Dengue is a systemic infection caused by dengue virus (DENV), a member of the Flaviviridae family and Flavivirus genus, that includes four serotypes (DENV 1 to DENV 4) (Guzman and Harris, 2015) . Dengue is the most important mosquito-borne viral diseases causing more than 96 million infections per year with approximately 3.6 billion people at risk, affecting more than 100 countries around the world (Hasan et al., 2016; Simmons et al., 2012) . DENV infection can be an asymptomatic illness or can produce a febrile illness (dengue fever, DF) which can lead to the severe disease complications, dengue hemorrhagic fever (DHF) or the dengue shock syndrome (DSS) (Hadinegoro, 2012) . Currently, there are no specific drugs to treat the infection with DENV or a fully effective vaccine. Indeed, viral factors such as the high genetic variability among the four serotypes of DENV (Lim et al., 2013) , antibody-dependent enhancement (ADE), and cross-reactivity with other Flavivirus such as Zika virus, make difficult to obtain a fully effective vaccine (Halstead and Russell, 2016; Villar et al., 2015) .
For this reason, development of therapeutic strategies with a panserotype effect is a priority. One possibility for the development of therapeutic strategies is to identify host factors that are usurped by DENV for replication (Acosta and Bartenschlager, 2016) . A common feature among the members of the Flaviviridae family is the induction of cell membranes formation in the endoplasmic reticulum (ER) that forms part of structures, rich in lipids, known as replication complexes (RC) (Welsch et al., 2009 ). On the other hand, different lipids, such as cholesterol, are essential components of the virion (Carro and Damonte, 2013) and cholesterol is also required for RC formation (Rothwell et al., 2009a; Soto-Acosta et al., 2013) . Thus, cholesterol could represent a key element at multiple stages of DENV replicative cycle. The cellular cholesterol content depends on the balance between uptake and de novo synthesis (Simons and Ikonen, 2000) . Previous studies conducted by our group, reported an increase in the low-density lipoprotein receptor (LDLr) on the cell surface at early times after DENV infection (Soto- Acosta et al., 2013) , suggesting that extracellular cholesterol is an essential source of this compound during DENV infection. Given the fact that several molecules are cholesterol receptors in the cell, we decided to study the participation of the Niemman-Pick C1-Like 1 (NPC1L1) receptor, which is a crucial molecule for the absorption and homeostasis of cholesterol in the human body (Betters and Yu, 2010a) . This receptor is found on the cellular surface of enterocytes and hepatocytes and is responsible for the cellular absorption of cholesterol in hepatocytes (Jia et al., 2011) . Some evidence suggests that the molecular mechanism for cholesterol absorption by the NPC1L1 receptor is dependent on clathrin-mediated endocytosis (Betters and Yu, 2010b) . Interestingly, the internalization of the receptor can be blocked by ezetimibe, a novel FDA-approved drug used to lower serum cholesterol in patients with dyslipidemia, when other lipid-lowering drugs have https://doi.org/10. 1016/j.antiviral.2018.10.024 Received 18 May 2018; Received in revised form 25 October 2018; Accepted 26 October 2018 failed (Betters and Yu, 2010b; Chang and Chang, 2008; Weinglass et al., 2008) . Our results indicate that NPC1L1 receptor participates actively in the cholesterol uptake during DENV infection and that the drug ezetimibe inhibits DENV infection in the human hepatoma cell line (Huh-7) by blocking the NPC1L1 receptor.
Materials and methods

Cell culture, virus, and reagents
The human hepatoma-derived cell line Huh-7 (Kindly donated by Dr. Ana Maria Rivas, Autonomous University of Nuevo León) and the Vero cells (Green monkey kidney cells, ATCC CCL-81) were grown in advanced DMEM (complete medium) supplemented with 2 mM glutamine, penicillin (5 × 10 4 ) streptomycin (50 μg/mL), 8% fetal calf serum (FCS) and 1 mL/L of amphotericin B (Fungizone) at 37°C and a 5% CO 2 atmosphere.
The propagation of DENV serotype 2 (New Guinea strain) and DENV serotype 4 (H241 strain) was carried out using CD-1 suckling mice brains (provided by the Unidad de Producción y Experimentación de Animales de Laboratorio (UPEAL)). The Brain extracts from MOCK-infected CD-1 suckling mice were used as a control. Viral titers were determined by foci forming units assay in Huh-7 cells.
As reagents, anti-prM-E monoclonal 2H2 (ATCC ® HB-114) antibody,
anti-E (Genetex), anti-NS3 (Genetex) and anti-C (Genetex) antibodies were used in flow cytometry and confocal microscopy to stain DENV viral proteins. The mouse anti-NPC1L1 (Santa Cruz Biotechnologies) polyclonal antibody was used to stain the Niemann-Pick C1-Like 1 receptor on the cellular surface. The drug Ezetimibe was used for the inhibitions assays and was obtained from Cayman Chemical (Ann Arbor, MI).
DENV infection and treatment
The Huh-7 cells seeded in 12-wells plate format at 70-80% of confluence were infected with DENV (serotype 2 or 4) at a multiplicity of infection (MOI) of 3 in medium supplemented with 1% of FCS for 2 h (h) at 37°C. Later, cells were washed three times with HANKS' solution and later the inhibition assay was performed using vehicle-treatment (Ethanol) or treatment with ezetimibe in complete medium for 48 h at 37°C.
Cell viability assay and IC 50 determination
The cell viability in cells treated with vehicle or with increasing concentrations of ezetimibe (0 μM (vehicle), 25 μM, and 50 μM ezetimibe) for 48 h at 37°C was assayed using propidium iodide (PI) and MTT methods. The cell viability was interpreted as the percentage of live cells by flow cytometry (BD LSR Fortessa™) by the PI method, while the MTT method was evaluated by spectrophotometry (BioTek ELx800) measuring the absorbance at 540 nm. The IC 50 was calculated over a broader range of concentrations (5, 10, 15, 25, 45, 50, 60 μM ezetimibe) and the data was analyzed in the Graph Pad Prism software.
Viral yield
Supernatants from infected untreated and treated cells were used to determine the viral yield using foci forming units (FFU) assay. Briefly, confluent monolayers of Huh-7 cells grown in 96-well plates were incubated with serial dilutions of supernatants from DENV-infected untreated or treated cells (final volume 50 μL) and incubated for 2 h at 37°C to allow viral absorption. Then, the inoculum was removed, the cells were washed three times with HANKS' solution, and 200 μL of the complete medium was added. The medium was removed 48 h post-infection (hpi) and the cells were fixed with 1% formaldehyde, permeabilized for 20 min (0.1% saponin and 1% FCS, in 1X PBS), incubated with the 2H2 anti-prM-E monoclonal antibody for 2 h at room temperature (RT), and detected with the anti-mouse Alexa 488 (Life technologies) secondary antibody. Foci were quantified under the fluorescence microscopy and expressed as Foci Forming Units per milliliter (FFU)/mL).
Quantification of the viral genome by qRT-PCR
The qRT-PCR was performed as previously described (BautistaCarbajal et al., 2017) . Briefly, the cDNA was obtained by RT-PCR using 1 μg of total RNA from each experimental condition, the enzyme ImpromII (Promega), and random primers (0.025 μg/μL) (Promega) with the following conditions: 25°C for 5 min, 42°C for 60 min, and 70°C for 15 min (Veriti Thermal Cycler, Applied Biosystems). The qPCR was performed with the SYBR Fast universal kit (Chukkapalli et al.) , 5 μL of 2X Master Mix, 1 μL of cDNA, and the primers previously described in an Eco Illumina System with the following conditions: 2 min at 50°C, 2 min at 95°C, 40 cycles of 5 s at 95°C, and 30 s at 55°C.
Western blot assay
Huh-7 cells were infected with DENV 2 or 4 at a MOI of 3 and treated with ezetimibe (0, 25 and 50 μM). Cell lysates were obtained and analyzed at 48 hpi to determine the presence of the NS3 protein as infection control. A total of 35 μg of protein extract, preheated at 95°C for 10 min in the presence of 3% β-mercaptoethanol, were separated by electrophoresis in 10% SDS-PAGE and transferred to nitrocellulose membrane (Bio-Rad) and immunoblotting using rabbit polyclonal antibody directed against the NS3 protein (GENETEX GTX124252). In the case of NPC1L1 protein (Santa Cruz Biotechnology sc-166802), a mouse monoclonal antibody was used for its detection at the 0, 1, 3, 6 and 12 hpi. The proteins were detected by the use of Super Signal West Femto Chemiluminescent Substrate (Thermo Scientific), and densitometric analysis was performed using the ImageJ software (NIH) adjusting with the loading control α-GAPDH, and the results were plotted with Graph Pad Prism software version 6.0.
Flow cytometry and confocal microscopy
The Huh-7 infected untreated and treated cells were analyzed by flow cytometry and confocal microscopy to determine the percentage of infected cells and viral or cellular proteins localization. The cells were grown in 24-wells plates for confocal microscopy and in 12-wells plates for flow cytometry. The harvested cells or slides were fixed with 1% formaldehyde, and were permeabilized for 20 min with permeabilizing solution and were incubated with anti-prM-E (2H2), anti-NS3, anti-C, anti-E or anti-NS4A antibodies for 2 h at RT; only the anti-NPC1L1 antibody was incubated overnight at 4°C, with 10% FCS, 3% of Bovine serum albumin (BSA) and 10 mM of glycine, without permeabilizing solution. As secondary antibodies, a goat anti-mouse Alexa Flour 488, a goat anti-mouse Alexa Flour 405 and a goat anti-rabbit Alexa Flour 555 were used (Life Technologies). To stain intracellular cholesterol dye filipin III complex (Sigma) was used, and the nuclei were counterstained with Hoechst or propidium iodide (Life Technologies). The samples were observed in a Zeiss LSM700 laser confocal microscopy and images were analyzed with ZEN software v. 2010. Flow cytometry was performed in a BD LSR Fortessa™ , and the data were analyzed using the FlowJo v. 10 software.
Transmission electron microscopy
Mock-infected, infected untreated and ezetimibe treated Huh-7 cells were washed three times with PBS, fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 1 h at RT. Then, the cells were treated with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer for 1 h at RT and dehydrated gradually by different concentrations of ethanol and propylene oxide and included in Poly/ bed epoxy resin at 60°C during 24 h. Thin sections (70 nm) were stained with uranyl acetate and lead citrate and visualized in a Jeol JEM-1011 transmission electron microscope.
Cellular cholesterol quantification
The cholesterol content was quantified by fluorometric enzymatic assay using a kit (Cayman Chemical Company, Ann Arbor, MI, USA), following the manufacturer's instructions. MOCK-infected or DENV-infected cells untreated or ezetimibe treated were lysed with lysis buffer (Chloroform, isopropanol, NP-40, 7:11:0.1). Fluorescence was detected using emission wavelengths of 585 nm in a microplate reader (Infinite 
Virus binding assay
The Huh-7 cells in suspension were pre-treated with 50 μM of ezetimibe or anti-NPC1L1 antibody (diluted 1:100) during 2 h at 37°C. Later, the cells were washed three times with PBS and were incubated with DENV 2 or DENV 4 at 4°C for 30 min. Then, cells were fixed at RT for 20 min with 1% formaldehyde, blocked with 2% FCS, incubated with anti-E MAb antibody (Genetex) diluted 1:100, and detected with goat anti mouse-Alexa 405 antibody (Life Technologies). Finally, 10,000 events were quantified by flow cytometry (BD LSR Fortessa™) and the data were analyzed with the FlowJo v. 10 software. Total DENV-and MOCK-infected cells extracts were separated by SDS-PAGE and analyzed by Western-blot using anti-NPC1L1 antibodies. Anti-GAPDH antibody was used as a load control.
Virus entry assay
Huh-7 cells were incubated within the absence (mock) or with DENV 2, and these last were treated with 0 μM or 50 μM of ezetimibe at 4°C for 5 min to synchronize the infection. Then, the temperature was increased to 37°C for 1 h to allow virus internalization. The cells were washed with acid glycine to inactivate the noninternalized viral particles. Finally, the samples were analyzed by confocal microscopy using a rabbit anti-C polyclonal antibody (GENETEX), and goat anti-rabbit Alexa 555 (Life Technologies) as a secondary antibody. As a control, Huh-7 cells were incubated with DENV 2 and the anti-dengue virus Eglycoprotein-specific monoclonal antibody (4G2) (MILLIPORE) to block virus adsorption to cells.
Statistics
For the statistical analysis, the Graph Pad Prism software version 6.0 was used. Numerical data were expressed with the value of the means and the standard deviation (SD) or standard error of the mean (SEM). For inhibition assays, the foci tests and the qRT-PCR the Kruskal-Wallis nonparametric test was used for multiple comparisons with the Dunn posthoc test. For the percentage of infected cells in the flow cytometry, the Student's t-test with the Welch correction was used. Statistical significance was established at the 95% level (p = < 0.05).
Ethics statement
This study was conducted in accordance with the Official Mexican Standard Guidelines for Production, Care and Use of Laboratory Animals (NOM-062- ZOO-1999 ) and the protocol, number 048-02, was approved by the Animal Care and Use Committee (CICUAL) at CINV-ESTAV-IPN, Mexico.
Results
The amount of NPC1L1 receptor on cell surface increases during DENV infection
Since the primary role of the Niemann-Pick C1-Like 1 (NPC1L1) receptor is the cholesterol uptake, and cholesterol is essential for DENV infection, the first step was to determine if this receptor was present on the cell surface during DENV infection. Thus, non-permeabilized Fig. 2 . Ezetimibe does not alter cell viability and sequesters the NPC1L1 receptor on the cell membrane. Huh-7 cells were incubated in the absence of 0 (vehicle = ethanol), or in the presence (25 or 50 μM) of ezetimibe and cell viability was evaluated by incorporation of (A) propidium iodide (IP) or (B) by MTT assay. The graphs show the percentage of living cells treated for 48 h. (C) Huh-7 cells were infected with DENV 2 and treated with 50 μM ezetimibe, fixed at 1, 3, 6 and 12 h post-infection (hpi) and the presence of NPC1L1 receptor (green) on the cell surface was analyzed by confocal microscopy, nuclei were stained with the nuclei of the cells were stained with Hoechst (Blue).
uninfected (MOCK-infected) and DENV-infected Huh-7 cells were incubated with the anti-NPC1L1 antibody and analyzed by confocal microscopy and flow cytometry. Although the receptor levels on the surface of the cells are similar at 0 h post infection (hpi) between the dengue-infected cells and the MOCK-infected cells ( Fig. 1 A and B) , a significant increase in the amount of NPC1L1 receptor on the cell surface of dengue-infected cells compared to the MOCK-infected was observed at 1 hpi ( Fig. 1 A and B ) (p = < 0.0001). Interestingly, at 3 hpi an abrupt reduction in the fluorescence on the surface of DENV infected cells was observed, suggesting that the receptor was internalized ( Fig. 1 A and B) (p = < 0.0001). This possibility is supported by the fact that the total amount of NPC1L1 receptor does not change in permeabilized cells analyzed by confocal microscopy (Fig. 1A) , by flow cytometry (Fig. 1 C) (p = ns) and by Western-blot (Fig. 1 D) . At 6 hpi, an increase in the amount of receptor was observed ( Fig. 1 A and B) . This increase is higher at 12 hpi ( Fig. 1 A and B) . These results suggest that DENV infection induces an increase of the NPC1L1 receptor on the cell surface during viral entry (at 1hpi) without changes in the NPC1L1 protein expression. The increase at 1 hpi and decrease in the amount of the receptor at 3 and 6 hpi could be related to the cholesterol uptake by internalization and recycling of the receptor (Ge et al., 2008) .
Ezetimibe reduces DENV infection
Once we determined that the amount of NPC1L1 receptor on the surface of Huh-7 cells increase early after infection, we decided to analyze its importance during DENV-2 and DENV-4 infection. We decided to use both serotypes because DENV-2 has been associated with severe disease while DENV-4 is claimed to lead to a milder illness (Nisalak et al., 2003; Sasmono et al., 2015; Vaughn et al., 2000) . To investigate this fact, the cells were treated with different concentrations of ezetimibe or vehicle (0 μM). Although ezetimibe has not a negative effect on cell viability evaluated by IP and MTT methods ( Fig. 2 A and  B) , it causes an arrest of the receptor on the cell membrane of infected cells at 1, 3, 6 and 12 h post-infection, as could be observed by confocal microscopy from non-permeabilized cells (Fig. 2 C) . Interestingly, ezetimibe was able to inhibit the four DENV serotypes (Fig. 3 A -D) , the IC 50 value was calculated by flow cytometry at 48 h post-infection, Remarkably, when 25 and 50 μM of ezetimibe were used, a significant reduction in viral yield, mainly at the concentration of 50 μM for DENV 2 (more than one log of UFF/mL, 95% decrease) (Fig. 3 E) and DENV 4 (2 logs of UFF/mL, 99% decrease) (Fig. 3 F) (p = 0.0146 and 0.0141, respectively) was detected. Since the best inhibitory effect of ezetimibe was observed at the concentration of 50 μM, this concentration was used for subsequent assays.
The next step was to evaluate the effect of ezetimibe in the number (Fig. 4 A) . When these differences were quantified by flow cytometry, the significant reduction in the percentage of infected cells was confirmed in ezetimibe treated cells infected with DENV2 (38.97% (p = 0.0140)) and DENV4 (39.43% (p = 0.0355)) (Fig. 4 B) , compared with vehicle-treated cells. All these results confirm that the NPC1L1 receptor plays an essential role during DENV infection. To exclude the possibility that the ezetimibe could have an offtarget effect the effect of this drug was tested in Vero cells, which are permissive to DENV infection but do not express the NPC1L1 receptor. As it can be observed, ezetimibe, used at the highest concentration tolerated by the cells, did not induce a reduction in the percentage of infected cells (p = 0.8145) compared with the vehicle, supporting the idea that the inhibition of DENV infection induced by ezetimibe in Huh7 cells is due to the blockage of the NPC1L1 receptor (Supplemental material, Fig. 1 A) , that is not present in Vero cells (Supplemental material, Fig. 1 B) . Moreover, the inhibition in DENV infection induced by ezetimibe in the presence of fetal calf serum (FCS), which contains cholesterol as low density (LDL) and high density (HDL) lipoproteins as well as free cholesterol (Forte et al., 1981) , was less pronounced than in cells incubated in the absence of FCS, supporting the idea that the cholesterol levels in infected cells are maintained by cholesterol synthesis and also by cholesterol uptake trough at least, two receptors: LDLr and NPC1L1. This last receptor inhibited by ezetimibe (Supplemental material, Fig. 2 A and B) .
Ezetimibe inhibits post-entry steps during DENV replicative cycle
In order to investigate the specific step in the DENV replicative cycle in which the NPC1L1 receptor is playing a role, the drug was added at different times of infection: 1) 6 h before infection (pretreatment), 2) 0, 3) 12, 4) 24 or 5) 36 hpi, according to the following scheme (Fig. 5 A) . While no differences in the percentage of infected cells were observed when cells were pretreated with ezetimibe, a significant reduction in the number of infected cells was observed in cells treated with ezetimibe after infection (Fig. 5 B) , supporting the idea that NPC1L1 is involved in steps after viral attachment. To analyze in further detail the specific step in which ezetimibe is inhibiting DENV infection, first, a viral binding assay in the presence of ezetimibe was performed. As shown in Fig. 6 A and 6 B, the amount of virus bound to the surface of cells infected with DENV2 or DENV4 was the same in the absence or the presence of ezetimibe, suggesting that the NPC1L1 receptor not is involved in viral attachment. To confirm this result and knowing that the binding site of ezetimibe to NPC1L1 is distinct from the anti-NPC1L1 antibody recognition site (Garcia-Calvo et al., 2005; Sainz et al., 2012) , the cells were incubated with the anti-NPC1L1 (Fig. 6 A and B) antibody and subsequently a viral binding assay was performed at 4°C. DENV2 or DENV4 attachment to the cell surface was not altered by the presence of the anti-NPC1L1 antibody confirming that this receptor is not involved in viral attachment to the cell surface.
To explore the possibility that ezetimibe could be disturbing the internalization of DENV, viral entry was analyzed by confocal microscopy using antibodies against C protein at a 1 hpi. While as expected, the presence of the anti-E protein antibody induced an important reduction in the presence of C in the cytoplasm of infected cells, the amount of C protein in the cytoplasm of infected cells was similar in ezetimibe treated and untreated cells, suggesting that the drug not alter DENV entry (Fig. 6 C) .
Finally, to analyze if viral translation and/or replication could be altered by ezetimibe, the amount of viral protein and viral genome was quantified by Western blot and qRT-PCR respectively in cells untreated or treated with ezetimibe. In agreement with the results of viral yield, a significant reduction in the RNA copy number (Fig. 7 A and B) for DENV 2 and DENV 4 (p = 0.0033 and 0.0347, respectively) was detected. In the same way, a significant reduction in the amount NS3 protein (Fig. 7C-E ) from DENV 2 and DENV 4 infected cells (p = < 0.0001) at both concentrations of the drug was observed, supporting the idea that ezetimibe blocks DENV infection inhibiting viral translation and replication.
Ezetimibe treatment affects the replicative complexes integrity
Since the main function of the NPC1L1 receptor is the uptake of cholesterol which is required for replication complexes (RC) formation, and translation and replication take place in these structures, the integrity of the RC in Huh-7 cells infected with DENV 2 and treated with ezetimibe was evaluated. The colocalization of E and NS3 proteins (Anwar et al., 2011 ) was analyzed using the Pearson's correlation Fig. 6 . NPC1L1 is not involved in DENV attachment or entry to Huh-7 cells. In the binding assay (A and B) , the Huh 7 cells in suspension were treated with ezetimibe or the anti-NPC1L1 antibody for 2 h prior the addition of the viral inoculum. The cells were allowed to interact with DENV 2 or DENV 4 for 30 min at 4°C, fixed and labeled with the anti-E antibody. The amount of virus bound to the surface of the cell was quantified by flow cytometry. (C) Huh-7 cells were incubated with mock or DENV 2 and these last were treated with 0 μM or 50 μM ezetimibe for 1 h. As a control, Huh-7 cells were incubated with DENV 2 and the anti-E monoclonal antibody (4G2) to block virus adsorption to cells. All the samples were fixed after 1 h and the viral C protein (Red) was evaluated by confocal microscopy. The nuclei were stained with Hoechst (Blue). Representative imagines of each condition are shown. coefficient and the Mander's correlation coefficient by confocal microscopy ( Fig. 8 C and D) . In the absence of ezetimibe, almost 100% of the cells were infected, and a compact and perinuclear distribution of both viral proteins was observed (Fig. 8 A and B) with a positive Pearson's colocalization coefficient (0.4683 ± 0.1458) (Fig. 8 C) . However, a substantial reduction in the number of infected cells, as well as a diffuse perinuclear distribution of viral proteins, was observed in infected cells treated with ezetimibe (50 μM) (Fig. 8 B) , with a negative Pearson's colocalization coefficient (−0.1154 ± 0.2288) (p = < 0.0001) (Fig. 8 C) , in the same way, it was observed when the Mander's correlation coefficient was calculated (Fig. 8 D) . These results suggest that blocking of cholesterol uptake by ezetimibe through the NPC1L1 receptor altered RC integrity. To confirm the effect of ezetimibe on RC integrity, Huh-7 cells were mock infected or infected with DENV and untreated and treated for 48 h with ezetimibe and analyzed by transmission electron microscopy (TEM). In the TEM analysis were assessed 200 cells profiles for each experimental condition. The DENV-infected or vehicle-treated (0 μM ezetimibe) cells; showed membrane invaginations in the endoplasmic reticulum (ER) such as the formation of membrane packets (Vp) that contained double-membrane vesicles (Ve), and tubular structures (T), which were not found in mock-infected cells (Fig. 9A-D) . Moreover, in these infected cells virus-like particles (Vi) around membrane vesicles were observed. Vi had electron-dense nature and its size and presence of a membranous layer, strongly suggesting that it represents viral particles. Additionally, it was remarkable the observation of structures similar to ER-derived organelles called lipid droplets (LDs) (Roingeard et al., 2008) at the periphery of the viral RC (Fig. 9 D) . However, in the ezetimibe DENV-infected cells, nor the RC neither the Vi was observed. Furthermore, the ER had no alterations in its membrane, and lipid droplets were absent (Fig. 9 E and F) , confirming the deleterious effect of ezetimibe in RC formation. The absence of RC in different ezetimibe treated infected cells analyzed by TEM is also observed in the supplemental material, Fig. 3 .
To confirm that the blockage of NPC1L1 receptor causes a reduction in cholesterol accumulation in the infected cells, the levels of cholesterol present in DENV-infected cells were evaluated in vehicle-treated and ezetimibe treated cells for 48 h by confocal microscopy and by a fluorometric assay. As it was described previously (Soto- Acosta et al., 2013) , an increase in cholesterol levels was observed in infected cells compared to MOCK-infected cells (Fig. 10A-C) . Moreover, filipin III dyed cholesterol was detected collocating with the non-structural protein 4A (NS4A) (a component of the RC (Miller et al., 2007) ) in the perinuclear region. However, in the ezetimibe treated infected cells, a reduction in the amount of cholesterol (Fig. 10A-C) as well as in the were treated with 25 and 50 μM of ezetimibe or vehicle (0 μM) for 48 h. The viral RNA and viral NS3 protein levels we determined by qRT-PCR (A and B) and Western blot assays (C-E), respectively. The log of the number of copies of RNA ± SD and relative band intensity from three independent assays in duplicate is presented. *p= < 0.05, **p= < 0.001. number of infected cells was observed.
All these results indicate that NPC1L1 receptor is involved in cholesterol accumulation required for RC formation during DENV infection. Thus, ezetimibe represents an effective antiviral drug for DENV infection.
Discussion
The opportunity offered by host-directed antiviral therapy (HDA), targeting host factors that are usurped by DENV for replication, is promising. Given the genetic austerity of the viruses, it depends on cellular factors and organelles to complete its viral cycle. One of the cellular components required during DENV infection is the cholesterol (Faustino et al., 2014; Soto-Acosta et al., 2013; Villareal et al., 2015) . Moreover, changes in serum lipid profile have been correlated with clinical manifestations in DENV infected patients (Biswas et al., 2015; Durán et al., 2015; Osuna-Ramos et al., 2018; Suvarna and Rane, 2009; van Gorp et al., 2002) . Thus, there is sufficient evidence to conclude that cholesterol and lipoproteins have a fundamental role during DENV infection (Faustino et al., 2014; Soto-Acosta et al., 2013; Villareal et al., 2015) . Cholesterol is an essential component of the cell membranes and is essential for the adequate cellular functioning (Fernández et al., 2004; Simons and Ikonen, 2000) . Cholesterol levels in the cells are controlled by biosynthesis, efflux from cells, and uptake (Simons and Ikonen, 2000) . Previous studies carried out in our laboratory have shown that the increase in cholesterol levels in infected cells are related to 1) an increased activity of HMG-CoA (3-hydroxy-3-methylglutarylcoenzyme A) reductase enzyme, through the dephosphorylation of AMPK (AMP-activated protein kinase); and with 2) an augment in cholesterol uptake by the increase in the amount of LDL receptor on the cell surface, . Therefore, treatment with statins, which inhibit the activity of HMG-CoA reductase, or metformin which activates APMK in cellular and/or animal models appears promising against DENV infection (Martinez-Gutierrez et al., 2014; Rothwell et al., 2009b; Soto-Acosta et al., 2017 . However, while lovastatin treatment was not able to inhibit DENV infection in a clinical trial in humans (Whitehorn et al., 2016) , the metformin reduced clinical complications caused by DENV infection in diabetic patients (Htun et al., 2018) , supporting the idea that the cholesterol is required during DENV infection. Since cholesterol is not only obtained by an increase in cholesterol synthesis but also through cellular receptors such as the LDLr (Soto- Acosta et al., 2013 ) the function of other cholesterol receptors such as NPC1L1 receptor in DENV infection was evaluated.
Interestingly, in our study, we observed an increase of the NPC1L1 receptor on the cell surface during the first hour after infection as it was described previously with the LDLr (Soto- Acosta et al., 2013) . Subsequently, at 3 and 6 h post-infection a reduction of the NPC1L1 receptor on the cell surface was observed. However, unlike what was reported with LDLr in DENV infection, at 12 hpi we observed an increase of the NPC1L1 receptor on the cell membrane. Since the same levels of receptor NPC1L1 were documented in permeabilized DENV infected, it is possible to suggest that at 1 and 12 hpi the receptor is located on the cell surface and at 3 and 6 is mainly in the cytoplasm, probably moving the cholesterol inside the cell and recycling the receptor. Ge et al. de- scribed that when cholesterol is removed from the medium and later added to liver cells, 85% of the NPC1L1 receptor is located on the plasma membrane to capture it (Ge et al., 2008) . In the DENV-infected cells, this was observed when the cells require a higher amount of cholesterol, and it is uptake from the media at early times. This finding suggests that binding or entry of DENV triggers cholesterol accumulation in the cell via LDLr and NPC1L1 receptor, but during viral replication, the cholesterol requirement could increase again, and it is obtained through the NPC1L1 receptor and by the increase in cholesterol synthesis by the HMG-CoA reductase . It is known that the NPC1L1 receptor is a 145 kDa protein involved in the uptake of cholesterol in liver cells, which can be blocked by ezetimibe, a drug approved by the FDA as cholesterol-lowering therapy (GarciaCalvo et al., 2005) . Our results suggest that ezetimibe can reduce the production of new viral particles, inhibits the DENV genome synthesis and reduce viral protein synthesis of DENV 2 and DENV 4 by inhibiting the uptake of extracellular cholesterol and blocking the NPC1L1 receptor by arresting it in the cell membrane during the first 12 h of infection. In addition, we were able to exclude that ezetimibe could be having an off-target effect since it was unable to inhibit DENV infection in Vero cells which lack the NPC1L1 receptor.
Since treatment with ezetimibe was not able to inhibit DENV binding or entry, a good amount of C protein at 1 hpi was detected in the cytoplasm of infected cells. However, in the presence of ezetimibe, a low amount of E and NS3 was observed at 48 hpi due to a reduction in cholesterol levels that caused a reduction in viral translation and replication, suggesting that the NPC1L1 receptor is not an entry factor for DENV, but it is required for an efficient viral replicative cycle. Likewise, for hepatitis B virus (HBV) ezetimibe blocked post-entry events but not binding or entry (Lucifora et al., 2013) . In contrast, ezetimibe was able to inhibit attachment and entry of Hepatitis C virus (HCV) considering to the NPC1L1 receptor as an entry factor (Sainz et al., 2012) . Interestingly, ezetimibe had a greater potential to inhibit the four DENV serotypes (logIC 50= 1.126-1.384 μM) than the observed for HCV and HBV infections (Lucifora et al., 2013; Sainz et al., 2012) , because the in vitro IC 50 for DENV was lower than the one reported for HBV and HCV, Fig. 9 . Ezetimibe affects the viral replication complex integrity. Transmission electron microscopy (TEM) analysis from Mock-infected (A and B), DENVinfected (C and D), and ezetimibe treated DENV-infected Huh-7 cells (50 μM) (E and F) at 48 h postinfection was performed. Nu, nucleus; Cy, cytoplasm; ER, endoplasmic reticulum; Ve, double-membrane vesicles; Vp, membrane packets; T, tubular structures; Vi, virus-like particles; and LD, lipid droplet.
supporting the idea that ezetimibe is a good candidate as an anti-DENV drug. It is important to notice that the reduction in viral yield, the inhibition in the amount of viral genome and proteins after treatment with ezetimibe, can be considered as a consequence of the loss of the integrity of RC, because a reduction in cholesterol levels, causes an inhibition of the RC formation in DENV-infected cells (Anwar et al., 2011; Miller et al., 2007) . The confocal microscopy and TEM analysis demonstrated that the cholesterol uptake blockage by ezetimibe affects the integrity of the membrane vesicles reported as RC in DENV infected cells (Junjhon et al., 2014; Reyes-Ruiz et al., 2018; Welsch et al., 2009) .
Additionally, a large number of LDs at the periphery of the viral RC observed in infected cells (Samsa et al., 2009) were also disrupted in the presence of ezetimibe. Thus, the life cycle of LDs, which begin when fatty acids and sterols enter into the cell (Guo et al., 2009; Thiam et al., 2013) , is blocked by Ezetimibe reducing the LDs formation. A disruption of RC integrity has also been observed in DENV-infected cells treated with drugs with hypolipidemic properties such as NDGA which causes a reduction in the colocalization of the viral proteins E and NS3 in the perinuclear region (Soto- Acosta et al., 2014) .
On the other hand, since DENV infection stimulates the accumulation of cholesterol in RC through the activation of HMG-CoA reductase, drugs such as metformin (AMPK activator that reduces HMG-CoA reductase activity) and lovastatin (HMG-CoA reductase inhibitor), both with hypolipemic activity, decreased the colocalization of the nonstructural protein 4A (NS4A) with cellular cholesterol (stained with filipin III) (Soto- , corroborating the importance of cholesterol in the formation and integrity of RC during DENV infection. The fact that ezetimibe reduces the cellular cholesterol levels confirms the importance of exogenous cholesterol in the integrity and formation of RC during DENV replication. In this work, the impact of the ezetimibe treatment in DENV infection in Huh-7 cells was analyzed in attachment, entry, translation, replication, replicative complex formation and virus production. The low amount of infected cells, as well as the low amount of negative-strand RNA in infected and treated cells, does not allow us to analyze negative strand levels. However, our qRT-PCR assays of positive-strand levels clearly showed the reduction in viral Fig. 10 . Ezetimibe reduces cellular cholesterol and disrupts the replication complexes formation. Uninfected (MOCK) and infected (48 h) Huh-7 cells untreated (0 μM) or treated with ezetimibe (50 μM) were incubated with the Filipin III complex (blue) and anti-NS4A antibody (green) and were analyzed by confocal microscopy. The nuclei were stained with propidium iodide (red). (B) Cholesterol levels were evaluated by pixels analysis, showing the mean fluorescence intensity (MFI) of Filipin III complex, and by a (C) fluorometric enzymatic assay. *p= < 0.05, **p= < 0.01. replication in the presence of ezetimibe. Furthermore, the impact of ezetimibe and other cholesterol-lowering drugs in viral maturation as well as in the lipid composition of the new viral particles produced is unknown. Further studies determining the proportion of mature versus immature viral particles as well as the amount of cholesterol and other lipids present in the membrane of the new viral particles generated from cells infected and treated with ezetimibe and other cholesterollowering drugs are required to understand the total impact of the reduction in cholesterol levels in the maturation of DENV.
In summary, in the present study, we demonstrate that the NPC1L1 receptor plays an essential role in the cellular cholesterol accumulation during DENV infection. It is possible that this receptor is working in collaboration with the LDLr to uptake cholesterol from media early after DENV infection. Since there are multiple other cellular receptors responsible for cholesterol uptake, such as the scavenger receptor class B type I (SR-BI) receptor (Li et al., 2013) , the participation of those receptors need to be evaluated.
Thus, our results indicate that the antiviral effect induced by ezetimibe is caused by a reduction of cholesterol uptake, which avoid the RC formation reducing the viral genome replication and translation and the formation of new viral particles. These results together with our previous findings allow us to conclude that during DENV infection there is an increase in cellular cholesterol levels due to an increase in cholesterol synthesis and an increase in cholesterol uptake through two different receptors LDL (Soto- Acosta et al., 2013) and NPC1L1 receptors. Finally, the requirement of extracellular cholesterol during DENV infection can be exploited with the use of cholesterol-lowering drugs. Since ezetimibe is an FDA-approved drug, it can be a suitable candidate for an HDA therapy for DENV infection.
